just frustrated... been waiting for this forever. I really thought we would get a ton of upgrades on events and rocket up. Do you think we could base above 40 and make a meaningful move up in the next 30 days ?
1. CANCER DX
A.I'm hearing chatter their new Cancer DX test will be unveiled in Q4.
B: Does it need FDA approval?
C. Has it been approved for reimbursements by health care ?
D. Do they commercial roll-out plan ?
2. BALANCE SHEET
A. BTX is burning 40mm a year and have 31MM in Cash, anyone worried ?
B. An offering could come Sub 2:50 ? or some quasi preferred share deal as they released a few days ago.
Thanks for your time.
Hi Pepsi. I see the ADX is at 25.442 getting higher as 30 usually is showing me a new trend has begun. do you agree with this reading and my analysis. thanks
TTOO is looking very cheap down here for a major disruptive technology that can saves life's and hospitals tons of money..
regarding the offering great question. My gut answer based on experience is that you can never count on a buy out even if its your end game or a viable exit. thus, you need to be prepared for a deal not going , secondly, a depleting war chest can weaken your leverage - stance in a protracted negotiation as the acquiring party can use it against you if when negotiating in good faith. The more i ponder a buy out the more makes it makes sense from a mass global roll out approach. potential candidates , usually suspects all have synergistic tie ins. whether it be relationships with doctors, sales teams, lab scalability and ins with the reimbursers.
great points Bio. Alot of my thesis on a buy out is based on my own jaded experiences of getting products to market .I just think they see the leverage and economies of scale by walking in a established foot print versus trying to cut out there own. regarding reimbursements, i believe this will come yet not without resistance. Yet, I agree with MGMT strategy of letting the data due the talking. albeit with out it in place any roll-out will be limited. but, lets say that TROV turns on the facet of testing with a discount prior to reimbursement approval therby establishing the market then just change the billing model post approval. now , imagine a established testing company behind them durig the beta roll out . just challenging conventional thinking. as, my own start up days are behind me.
I make investments based on market opportunity. Which led me to get involved here. Yet, as my posts highlight i use technical indicators to enter and exit. After, thinking through the different sides of this opportunity this weekend. I believe MGMT might be priming this for acquisition in the near term. I was led to this believe by their quasi undefined macro roll out strategy , including there lack of ramp up of sales reps. Thus, it leads me to consider they want to team up with a company that has an established and creditable sales infrastructure in place. Thereby; allowing them to add their product on someones menu. They have been kinda cagey about disclosing REV model and very adamant about data, data which also tells me they´re not focused on making money but focused on building the barriers to entry ( IP ) and getting proof of concept and willingness of adoption that all lends itself to getting the best deal possible. As, the matrix of valuation will not be based on current or historical sales but future sales. thus, it comes down to IP and Adoption. My gut tells me they are talking to potential buyers now .... All the above is my humble often naive opinion.
very little buy side interest. I agree with your early analysis of being in a trade range here with a 5 floor. i believe we could fill gap at 5.78. buyers will step in. yet, we will still have the issue of over 3mm shares short .
Nice Technical DD JR. I believe the volume next week will really help us understand the tale here. As, nervous retail shorts could have created a melt up only to be leaned on by the generals. PS: great color on tomorrow makes liars of us. have a great wkend. Blessings .